T7 peptide -modified ZL006 long-circulating liposome and preparation method thereof
The invention discloses a T7 peptide-modified ZL006 long-circulating liposome which comprises phospholipid, cholesterol, methoxy-polyethylene glycol-phosphatidyl ethanolamine, T7 peptide-polyethylene glycol-phosphatidyl ethanolamine and therapeutically effective amount of ZL006. The invention also d...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Patent |
Language | Chinese English |
Published |
18.06.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention discloses a T7 peptide-modified ZL006 long-circulating liposome which comprises phospholipid, cholesterol, methoxy-polyethylene glycol-phosphatidyl ethanolamine, T7 peptide-polyethylene glycol-phosphatidyl ethanolamine and therapeutically effective amount of ZL006. The invention also discloses a preparation method of the T7-modified ZL006 long-circulating liposome. According to the T7-modified ZL006 long-circulating liposome, the medicine ZL006 is encapsulated in a lipid bilayer, so that the circulating time of the medicine in the body is greatly prolonged; by means of T7 peptide modification, the blood brain barrier penetration capability of the medicine is improved, the medicine for treating cerebral apoplexy is effectively and concentratedly transferred to the cerebral apoplexy part, the treatment effect of the medicine is furthest exerted, and meanwhile, the toxic and side effects of the whole body are reduced. |
---|---|
Bibliography: | Application Number: CN2014149462 |